iBio Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation (Details)

Basis of Presentation (Details) - USD ($)												1 Months Ended	2 Months Ended	3 Months Ended		4 Months Ended	6 Months Ended			8 Months Ended	12 Months Ended
Basis of Presentation (Details) - USD ($)	Jan. 11, 2021	Dec. 10, 2020	Dec. 08, 2020	Nov. 25, 2020	Jun. 30, 2020	Jun. 30, 2020	Jun. 17, 2020	May 13, 2020	Mar. 19, 2020	Oct. 31, 2019	Oct. 29, 2019	Jul. 27, 2020	Dec. 31, 2019	Jun. 30, 2020	Dec. 31, 2019	Jul. 27, 2020	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2020	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018	Jun. 20, 2018
Basis of Presentation [Line Items]
Accumulated deficit					$ (150,420,000)	$ (150,420,000)								$ (150,420,000)			$ (166,082,000)	$ (150,420,000)		$ (150,420,000)	$ (150,420,000)
Net Cash Used in Operating Activities																	(15,489,000)		$ (5,692,000)
Cash					$ 55,112,000	$ 55,112,000							$ 3,637,000	$ 55,112,000	$ 3,637,000		91,252,000	$ 55,112,000	3,637,000	55,112,000	55,112,000	$ 55,112,000	$ 4,421,000
Proceeds from exercise of warrants																	$ 0		$ 691,000	$ 6,400,000	$ 6,300,000
Net proceeds from underwritten public offering											$ 4,500,000
Number of shares issued during the period				30,184,399
Gross proceeds from issuance of common stock				$ 72,000,000							$ 4,500,000
Common Stock, Par or Stated Value Per Share					$ 0.001	$ 0.001								$ 0.001			$ 0.001	$ 0.001		$ 0.001	$ 0.001
Net Proceeds From Issuance Of Common Stock				68,800,000
Stock Issued During Period, Shares, Warrants Exercised										29,100,000			29,100,000					29,100,000	14,999,998
Lincoln Park 2020 Purchase Agreement
Basis of Presentation [Line Items]
Stock Issued During Period, Value, New Issues								$ 1,100,000
Number of shares issued during the period								1,000,000	815,827			2,673,000		16,800,000		19,470,000
Shares Issued, Price Per Share								$ 1.09
Number of shares agreed to be issued									1,000,000
Gross proceeds from issuance of common stock												$ 6,800,000				$ 25,200,000
Common Stock, Par or Stated Value Per Share									$ 0.001
Authorized value of shares									$ 50,000,000
Term of agreement									36 months
Net Proceeds From Issuance Of Common Stock Shares							30,200,000
Net Proceeds From Issuance Of Common Stock							$ 68,830,000										$ 107,600,000
Aggregate Common Stock Purchased									$ 50,000,000
Sales Agreement
Basis of Presentation [Line Items]
Authorized value of shares				100,000,000
Aggregate Common Stock Purchased				$ 100,000,000
Underwriting Agreement
Basis of Presentation [Line Items]
Number of shares issued during the period		29,661,017
Shares Issued, Price Per Share		$ 1.0955
Number of shares agreed to be issued			29,661,017
Net Proceeds From Issuance Of Common Stock		$ 32,300,000
Over allotment \| Underwriting Agreement
Basis of Presentation [Line Items]
Number of shares agreed to be issued			4,449,152
Common Stock
Basis of Presentation [Line Items]
Number of shares issued during the period											2,450,000
Shares Issued, Price Per Share											$ 0.20													$ 0.90
Stock Issued During Period, Shares, Warrants Exercised															3,140,000
Common Stock \| Lincoln Park 2020 Purchase Agreement
Basis of Presentation [Line Items]
Net Proceeds From Issuance Of Common Stock																	$ 4,700,000
Subsequent event \| Over allotment \| Underwriting Agreement
Basis of Presentation [Line Items]
Number of shares issued during the period	4,240,828
Net Proceeds From Issuance Of Common Stock	$ 4,700,000
UBS Securities, LLC ("UBS")
Basis of Presentation [Line Items]
Net proceeds from underwritten public offering							$ 72,000,000
Number of shares issued during the period					17,420,000	2,360,000											10,410,000
Gross proceeds from issuance of common stock					$ 37,800,000	$ 5,500,000											$ 28,400,000